Treatment of bone metastases from breast cancer and myeloma with pamidronate.
28 patients with progressing painful bone metastases (18 breast cancer, 9 myeloma and 1 low grade lymphoma) received pamidronate 60 mg by 24 h continuous infusion for at least 2 courses (range 2-12). In patients urinary calcium and hydroxyproline excretion significantly decreased in relation to diminution of bone resorption. 9 of 18 breast cancer patients and 8 of 9 evaluable patients with myeloma had symptomatic improvement. Sclerotic areas of previously lytic lesions appeared in 8 breast cancer patients and in 1 myeloma patient. Transient fever developed in 1 patient and local phlebitis in 2. Among the 28 patients, 15 did not receive any anticancer treatment or have any change of the anticancer therapy during pamidronate administration. Of 7 with breast cancer, 4 had an improvement of symptoms and 4 sclerosis on radiographs. Impressive control of symptoms was the major feature of 8 myeloma patients, but only 1 had radiographic sclerosis.
Thiébaud
D
D
Department of Internal Medicine, University Hospital, CHUV-06, Lausanne, Switzerland.
Leyvraz
S
S
von Fliedner
V
V
Perey
L
L
Cornu
P
P
Thiébaud
S
S
Burckhardt
P
P
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D001859:Bone Neoplasms / Q000188:drug therapy / Q000556:secondary*; D001862:Bone Resorption / Q000188:drug therapy; D001943:Breast Neoplasms / Q000378:metabolism*; D004164:Diphosphonates / Q000627:therapeutic use*; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D008875:Middle Aged; D009101:Multiple Myeloma / Q000378:metabolism*; D000077268:Pamidronate
D004164:Diphosphonates; D000077268:Pamidronate